Short answer
GLAUKOS Corp (GKOS) filed its Q3 2026 10-Q quarterly report on Oct 28, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $211M (up 58.0% year over year) with net income of $2M.
Q3 2026 key financials · XBRL
- Revenue
- $211M
- +58.0% YoY · +13.7% QoQ
- Net income
- $2M
- +112.4% YoY · +111.0% QoQ
- Operating margin
- 0.4%
- Gross margin
- 85.2%
- EPS (diluted)
- $0.03
- +110.3% YoY · +109.7% QoQ
Source: XBRL data from the GLAUKOS Corp (GKOS) Q3 2026 10-Q on SEC EDGAR. USD.
GLAUKOS Corp Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $211.0M, up 58% YoY from $133.5M, led by glaucoma and corneal health products
- Gross margin 85% vs 78% YoY, with net income $2.0M vs net loss $16.2M
- Best segment: corneal health revenue $59.0M, up 154% from $23.3M; international glaucoma worst growth, up 13% to $33.4M
- Cash flow: operating cash provided $40.9M vs $21.6M used YoY; cash, investments and restricted cash $339.8M vs $282.6M
- Outlook: $42.0M Huntsville Facility project, reimbursement uncertainty for potential iDose TR LCDs, Germany reimbursement challenges
Risk Factors
- No material changes from June 30, 2026 10-Q, per filing disclosure
- Regulatory risk: QMSR effective February 2, 2026, replacing FDA Quality System Regulation with ISO 13485:2016 requirements
- Near-term commercial risk: proposed LCDs from five MACs in May 2026 could impose conditions on iDose TR use
- Financial risk: accumulated deficit approximately $969.3 million, despite expected liquidity for at least 12 months
- Operational risk: sole San Clemente campus manufactures nearly all implanted device products, creating disruption concentration
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other GLAUKOS Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.